Richard Hopkins

NK:IO has appointed Richard Hopkins as Chief Executive Officer

NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its new Chief Executive Officer.

Hopkins has more than 14 years of experience spanning industry, government and academia. He joins the Imperial College spinout after serving as Vice President of Pre-Clinical and Clinical Translation at bit.bio, which saw him establish the company’s preclinical team and advance multiple cell therapy programmes.

He previously served as Head of Translation at bit.bio, following his positions as Senior Research Fellow and Research Director Immunology at Tessa Therapeutics.

He also held Research Fellow positions at the Agency for Science, Technology and Research (A*STAR) earlier in his career.

In his latest role, Hopkins will lead NK:IO’s efforts to advance its ovarian cancer therapy into preclinical development.

Mike Romanos, Co-Founder and former interim Chief Executive Officer, said: “Since Hugh Brady, Matt Fuchter and I founded NK:IO we have seen the company’s science develop to the stage where we have a truly robust platform with broad therapeutic potential… We are very pleased that Richard has joined us at this critical time to grow the company and take it into development…”